LCSW BA - Verona Pharma G Counsel
| VRNA Stock | USD 39.45 0.75 1.87% |
Insider
LCSW BA is G Counsel of Verona Pharma PLC
| Age | 55 |
| Address | 3 More London Riverside, London, United Kingdom, SE1 2RE |
| Phone | 44 20 3283 4200 |
| Web | https://www.veronapharma.com |
Verona Pharma Management Efficiency
The company has return on total asset (ROA) of (0.2805) % which means that it has lost $0.2805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7803) %, meaning that it created substantial loss on money invested by shareholders. Verona Pharma's management efficiency ratios could be used to measure how well Verona Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of December 11, 2024, Return On Tangible Assets is expected to decline to -0.19. In addition to that, Return On Capital Employed is expected to decline to -0.24. At present, Verona Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 19.3 M, whereas Return On Tangible Assets are forecasted to decline to (0.19).Similar Executives
| Showing other executives | INSIDER Age | ||
| Matthew MD | Ideaya Biosciences | N/A | |
| Margaret MBA | Amylyx Pharmaceuticals | 59 | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Keith CPA | Syndax Pharmaceuticals | 53 | |
| Tom Holmes | Amylyx Pharmaceuticals | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| MA MS | Inozyme Pharma | N/A | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| John Lewicki | Mereo BioPharma Group | 72 | |
| Murray MD | X4 Pharmaceuticals | 63 | |
| Chris Aiello | Amylyx Pharmaceuticals | N/A | |
| Renato Skerlj | X4 Pharmaceuticals | N/A | |
| Kristian Reich | MoonLake Immunotherapeutics | 58 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Peter BSc | Syndax Pharmaceuticals | 55 | |
| MS MBA | Inozyme Pharma | 47 | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Timothy Rolph | Akero Therapeutics | 70 | |
| MBA MBA | Inozyme Pharma | 65 | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.28 |
Verona Pharma PLC Leadership Team
Elected by the shareholders, the Verona Pharma's board of directors comprises two types of representatives: Verona Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Verona. The board's role is to monitor Verona Pharma's management team and ensure that shareholders' interests are well served. Verona Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Verona Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Caroline Diaz, Senior Affairs | ||
| LCSW BA, G Counsel | ||
| Matthew Casbon, Marketing Sales | ||
| Peter Spargo, Senior Controls | ||
| Kathleen MD, Chief Officer | ||
| David PharmD, CEO President | ||
| B ASIA, General Counsel | ||
| Kavita Aggarwal, Senior Affairs | ||
| Christopher Martin, Chief Officer | ||
| Nina Church, Ex Devel | ||
| Tara MPH, Chief Officer | ||
| David Zaccardelli, CEO Pres | ||
| Mark Hahn, Chief Officer | ||
| Kathleen Rickard, Chief Officer | ||
| Victoria Stewart, Director Communications | ||
| Ostra Jewell, Senior Resources | ||
| Andrew Fisher, General Counsel |
Verona Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Verona Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.78 | ||||
| Return On Asset | -0.28 | ||||
| Operating Margin | (6.94) % | ||||
| Current Valuation | 3.1 B | ||||
| Shares Outstanding | 81.83 M | ||||
| Shares Owned By Insiders | 3.99 % | ||||
| Shares Owned By Institutions | 88.99 % | ||||
| Number Of Shares Shorted | 5.98 M | ||||
| Price To Earning | (9.15) X | ||||
| Price To Book | 25.40 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.00) | Revenue Per Share 0.07 | Return On Assets (0.28) | Return On Equity (0.78) |
The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.